{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:42:22Z","timestamp":1785508942852,"version":"3.56.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>From a pathogenetic point of view, heart failure (HF) is characterized by the activation of several neurohumoral pathways with a role in maintaining the cardiac output and the adequate perfusion pressure in target organs and tissues. Decreased cardiac output in HF with reduced ejection fraction causes activation of the sympathetic nervous system, the renin angiotensin aldosterone system, arginine-vasopressin system, natriuretic peptides, and endothelin, all of which cause water and salt retention in the body. As a result, patients will present clinically as the main symptoms: dyspnea and peripheral edema caused by fluid redistribution to the lungs and\/or by fluid overload. By studying these pathophysiological mechanisms, biomarkers with a prognostic and therapeutic role in the management of edema were identified in patients with HF with low ejection fraction. This review aims to summarize the current data from the specialty literature of such biomarkers with a role in the pathogenesis of edema in HF with low ejection fraction. These biomarkers may be the basis for risk stratification and the development of new therapeutic means in the treatment of edema in these patients.<\/jats:p>","DOI":"10.3389\/fcvm.2022.910100","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:21:10Z","timestamp":1655443270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction"],"prefix":"10.3389","volume":"9","author":[{"given":"Roxana Mihaela","family":"Chiorescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana-Daiana","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor-Botond","family":"Buksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Mocan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Blendea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/eurheartj\/ehx628","article-title":"European Society of Cardiology: cardiovascular disease statistics 2017","volume":"39","author":"Timmis","year":"2018","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41569-021-00607-3","article-title":"Epidemiology of cardiovascular disease in Europe","volume":"19","author":"Townsend","year":"2022","journal-title":"Nat Rev Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation\/American Heart Association task force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1152\/ajprenal.00254.2010","article-title":"Increased renal ENaC subunits and sodium retention in rats with chronic heart failure","volume":"300","author":"Zheng","year":"2011","journal-title":"Am J Physiol Ren Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e002922","DOI":"10.1161\/CIRCHEARTFAILURE.115.002922","article-title":"Fluid volume overload and congestion in heart failure","volume":"9","author":"Miller","year":"2016","journal-title":"Circ Hear Fail."},{"key":"B7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers","volume":"12","author":"Borovac","year":"2020","journal-title":"World J Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/ajhp\/61.suppl_2.S4","article-title":"Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure","volume":"61","author":"Adams","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-physiol-031620-093431","article-title":"Renal denervation to treat heart failure","volume":"83","author":"Sharp Iii","year":"2021","journal-title":"Annu Rev Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000313721","article-title":"Fluid overload as a biomarker of heart failure and acute kidney injury","volume":"164","author":"Bagshaw","year":"2010","journal-title":"Contrib Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2016","journal-title":"Nat Rev Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J Vet Intern Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","article-title":"ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis","volume":"107","author":"Sim\u00f5es e Silva","year":"2016","journal-title":"Pharmacol Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ihj.2016.08.007","article-title":"Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - demystifying controversies","volume":"69","author":"Muneer","year":"2017","journal-title":"Indian Heart J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ki.1986.14","article-title":"Renal kallikrein-kinin system","volume":"29","author":"Scicli","year":"1986","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/Valsartan","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Hear Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/00041552-199307000-00016","article-title":"Clinical relevance of the natriuretic peptides in edematous states","volume":"2","author":"Lieberthal","year":"1993","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2019.01.091","article-title":"Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure","volume":"289","author":"Kobayashi","year":"2019","journal-title":"Int J Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e006769","DOI":"10.1161\/CIRCHEARTFAILURE.119.006769","article-title":"Prognostic value of dynamic changes in pulmonary congestion during exercise stress echocardiography in heart failure with preserved ejection fraction","volume":"13","author":"Coiro","year":"2020","journal-title":"Circ Hear Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.12680\/balneo.2018.198","article-title":"Quality of life \u2013 an important parameter of cardiac rehabilitation in heart failure patients","volume":"9","author":"Farca\u015f","year":"2018","journal-title":"Balneo Res J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/cells10020457","article-title":"Why do we not assess sympathetic nervous system activity in heart failure management: might GRK2 serve as a new biomarker?","volume":"10","author":"Bencivenga","year":"2021","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1530\/JOE-16-0146","article-title":"Effect of heart failure on catecholamine granule morphology and storage in chromaffin cells","volume":"230","author":"Mahata","year":"2016","journal-title":"J Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.3390\/ijms20133182","article-title":"Gladysheva IP. Renin activity in heart failure with reduced systolic function-new insights","volume":"20","author":"Sullivan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1753944720939383","DOI":"10.1177\/1753944720939383","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation","volume":"14","author":"Sano","year":"2020","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/HJH.0b013e328341a429","article-title":"Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems","volume":"29","author":"Di Comite","year":"2011","journal-title":"J Hypertens."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/biomedicines9121757","article-title":"Catestatin as a biomarker of cardiovascular diseases: a clinical perspective","volume":"9","author":"Bozic","year":"2021","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.11909\/j.issn.1671-5411.2021.01.007","article-title":"Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression","volume":"18","author":"Polyakova","year":"2021","journal-title":"J Geriatr Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1210\/en.2008-0318","article-title":"The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine\/paracrine modulator of cardiac inotropism and lusitropism","volume":"149","author":"Angelone","year":"2008","journal-title":"Endocrinology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/biom12020156","article-title":"Mart\u00ednez A. Adrenomedullin: not just another gastrointestinal peptide","volume":"12","author":"Bustos","year":"2022","journal-title":"Biomolecules"},{"key":"B33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ejhf.1366","article-title":"Adrenomedullin in heart failure: pathophysiology and therapeutic application","volume":"21","author":"Voors","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"B34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ejhf.1693","article-title":"Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission methods and results","volume":"22","author":"Pandhi","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/0735-1097(95)00338-X","article-title":"Increased plasma levels of adrenomedullin in patients with heart failure","volume":"26","author":"Nishikimi","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41440-021-00806-y","article-title":"Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases","volume":"45","author":"Kita","year":"2022","journal-title":"Hypertens Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40635-019-0255-0","article-title":"Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats","volume":"7","author":"Blet","year":"2019","journal-title":"Intensive Care Med Exp."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1093\/eurheartj\/ehaa757","article-title":"The ACCOST-HH trial","volume":"41","author":"Skurk","year":"2020","journal-title":"Eur Heart J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13613-016-0229-2","article-title":"Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock","volume":"7","author":"Tolppanen","year":"2017","journal-title":"Ann Intensive Care"},{"key":"B40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1536\/ihj.20-442","article-title":"Intravenous mineralocorticoid receptor antagonist use in acutely decompensated heart failure with diuretic resistance","volume":"62","author":"Girerd","year":"2021","journal-title":"Int Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/ijms20163886","article-title":"Normalizing plasma renin activity in experimental dilated cardiomyopathy: effects on edema, cachexia, and survival","volume":"20","author":"Sullivan","year":"2019","journal-title":"Int J Mol Sci Artic."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11883-014-0403-7","article-title":"Modulation of the renin-angiotensin-aldosterone system in heart failure","volume":"16","author":"George","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10741-021-10137-2","article-title":"Current and emerging drug targets in heart failure treatment","volume":"1","author":"Ghionzoli","year":"2021","journal-title":"Heart Fail Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.cjco.2021.03.001","article-title":"Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in COVID-19: meta-analysis\/meta-regression adjusted for confounding factors","volume":"3","author":"Lee","year":"2021","journal-title":"CJC Open."},{"key":"B47","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10096-020-04138-6","article-title":"COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection","volume":"40","author":"Beyerstedt","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"L301","DOI":"10.1152\/ajplung.00259.2020","article-title":"Angiotensin-converting enzyme 2 and COVID-19: Patients, comorbidities, and therapies","volume":"320","author":"Pathangey","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12916-021-02012-6","article-title":"Renin-angiotensin system blockers and COVID-19","volume":"19","author":"Vidal-Petiot","year":"2021","journal-title":"BMC Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.bcp.2007.12.015","article-title":"The apelin-APJ system in heart failure. Pathophysiologic relevance and therapeutic potential","volume":"75","author":"Japp","year":"2008","journal-title":"Biochem Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2013.09.001","article-title":"Apelin and its receptor APJ in cardiovascular diseases","volume":"428","author":"Yu","year":"2014","journal-title":"Clin Chim Acta"},{"key":"B52","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.109.134619","article-title":"[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease","volume":"54","author":"Maguire","year":"2009","journal-title":"Hypertension"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15386\/cjmed-380","article-title":"The apelin-APJ system in the evolution of heart failure","volume":"88","author":"Goidescu","year":"2015","journal-title":"Clujul Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1172\/JCI69608","article-title":"Apelin is a positive regulator of ace2 in failing hearts","volume":"123","author":"Sato","year":"2013","journal-title":"J Clin Invest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cardfail.2010.02.004","article-title":"Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction","volume":"16","author":"Chandrasekaran","year":"2010","journal-title":"J Card Fail"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5569410","DOI":"10.1155\/2021\/5569410","article-title":"ACE2 and apelin-13: biomarkers with a prognostic value in congestive heart failure","volume":"22","author":"Goidescu","year":"2021","journal-title":"Dis Markers."},{"key":"B57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.11613\/BM.2013.021","article-title":"Copeptin and its potential role in diagnosis and prognosis of various diseases","volume":"23","author":"Dob\u0161a","year":"2013","journal-title":"Biochem Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/ehf2.12231","article-title":"Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study","volume":"5","author":"D\u00fcngen","year":"2018","journal-title":"ESC Heart Fail"},{"key":"B59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2017.10.001","article-title":"Copeptin in heart failure: Review and meta-analysis","volume":"475","author":"Zhong","year":"2017","journal-title":"Clin Chim Acta."},{"key":"B60","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s11897-019-00447-w","article-title":"Cardiac biomarkers in advanced heart failure: how can they impact our pre-transplant or pre-LVAD decision-making","volume":"16","author":"Ebong","year":"2019","journal-title":"Curr Heart Fail Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/01.mnh.0000441053.81339.61","article-title":"Direct regulation of ENaC by bradykinin in the distal nephron. Implications for renal sodium handling","volume":"23","author":"Mamenko","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1152\/ajprenal.00606.2010","article-title":"O'neil RG, Pochynyuk O. Bradykinin acutely inhibits activity of the epithelial Na channel in mammalian aldosterone-sensitive distal nephron","volume":"300","author":"Zaika","year":"2011","journal-title":"Am J Physiol Ren Physiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1161\/HYPERTENSIONAHA.115.05838","article-title":"Urinary proteolytic activation of renal epithelial Na + channels in chronic heart failure","volume":"67","author":"Zheng","year":"2016","journal-title":"Hypertension."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1454986","DOI":"10.1155\/2017\/1454986","article-title":"Natriuretic peptides as biomarkers for congestive states: the cardiorenal divergence","volume":"2017","author":"Koratala","year":"2017","journal-title":"Dis Markers."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/CIRCULATIONAHA.120.046947","article-title":"Markers of myocardial stress, myocardial injury, and subclinical inflammation and the risk of sudden death","volume":"142","author":"Everett","year":"2020","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/s-0039-1679104","article-title":"Cardiac biomarkers: what is and what can be","volume":"3","author":"Jacob","year":"2018","journal-title":"Indian J Cardiovasc Dis women WINCARS."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.ihj.2018.01.002","article-title":"Sacubitril\/valsartan: a novel angiotensin receptor-neprilysin inhibitor","volume":"70","author":"Dargad","year":"2018","journal-title":"Indian Heart J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1753944718784536","article-title":"Sacubitril\/valsartan in cardiovascular disease: evidence to date and place in therapy","volume":"12","author":"Yandrapalli","year":"2018","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1177\/0300060518786907","article-title":"Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease","volume":"46","author":"Idzikowska","year":"2018","journal-title":"J Int Med Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12967-019-02165-2","article-title":"Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients","volume":"17","author":"Yagmur","year":"2019","journal-title":"J Transl Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12933-020-01155-9","article-title":"MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction","volume":"19","author":"Jensen","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7279036","DOI":"10.1155\/2018\/7279036","article-title":"Possible enzymatic downregulation of the natriuretic peptide system in patients with reduced systolic function and heart failure: a pilot study","volume":"2018","author":"Zaidi","year":"2018","journal-title":"Biomed Res Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/HYPERTENSIONAHA.115.06300","article-title":"Depressed corin levels indicate early systolic dysfunction before increases of atrial natriuretic peptide\/B-type natriuretic peptide and heart failure development","volume":"67","author":"Tripathi","year":"2016","journal-title":"Hypertension."},{"key":"B74","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/CIRCHEARTFAILURE.109.895581","article-title":"Original articles decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide","volume":"4","author":"Ibebuogu","year":"2011","journal-title":"Circ Heart Fail."},{"key":"B75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/ijms21010203","article-title":"Cardiac-specific overexpression of catalytically inactive corin reduces edema, contractile dysfunction, and death in mice with dilated cardiomyopathy","volume":"21","author":"Tripathi","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7150\/thno.22196","article-title":"Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update","volume":"8","author":"Suthahar","year":"2018","journal-title":"Theranostics"},{"key":"B77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","article-title":"Galectin-3 in heart failure: an update of the last 3 years","volume":"14","author":"Gehlken","year":"2018","journal-title":"Heart Fail Clin"},{"key":"B78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11010-019-03656-y","article-title":"Role of oxidative stress-related biomarkers in heart failure: galectin 3, \u03b11-antitrypsin and LOX-1: new therapeutic perspective?","volume":"464","author":"Lubrano","year":"2019","journal-title":"Mol Cell Biochem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10741-019-09858-2","article-title":"Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis","volume":"25","author":"Chen","year":"2019","journal-title":"Heart Fail Rev"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin","year":"2013","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/CIRCHEARTFAILURE.108.833707","article-title":"Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea","volume":"2","author":"Shah","year":"2009","journal-title":"Circ Heart Fail"},{"key":"B82","doi-asserted-by":"publisher","first-page":"8143737","DOI":"10.1155\/2020\/8143737","article-title":"Short-term prognosis value of sST2 for an unfavorable outcome in hypertensive patients","volume":"2020","author":"Farca\u015f","year":"2020","journal-title":"Dis Markers"},{"key":"B83","doi-asserted-by":"publisher","first-page":"7583690","DOI":"10.1155\/2019\/7583690","article-title":"Biomarkers of inflammation in left ventricular diastolic dysfunction","volume":"2019","author":"Mocan","year":"2019","journal-title":"Dis Markers"},{"key":"B84","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","article-title":"Established and emerging roles of biomarkers in heart failure","volume":"123","author":"Ibrahim","year":"2018","journal-title":"Circ Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1161\/CIRCHEARTFAILURE.113.000457","article-title":"Soluble concentrations of the interleukin receptor family member ST2 and \u03b2-Blocker therapy in chronic heart failure","volume":"6","author":"Gaggin","year":"2013","journal-title":"Circ Hear Fail."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/ijms22052299","article-title":"Cardiac T-Tubule cBIN1-microdomain, a diagnostic marker and therapeutic target of heart failure","volume":"22","author":"Li","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamacardio.2018.3539","article-title":"Association of a novel diagnostic biomarker, the plasma cardiac bridging integrator 1 score, with heart failure with preserved ejection fraction and cardiovascular hospitalization","volume":"3","author":"Shaw","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/BF02912874","article-title":"Biochemical markers of myocardial injury","volume":"22","author":"Nigam","year":"2007","journal-title":"Indian J Clin Biochem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3390\/cells9071679","article-title":"The ins and outs of cathepsins: physiological function and role in disease management","volume":"9","author":"Yadati","year":"2020","journal-title":"Cells."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/ejhf.1674","article-title":"The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach","volume":"22","author":"Hoes","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B91","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2217\/bmm-2017-0376","article-title":"Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction","volume":"12","author":"Oikonomou","year":"2018","journal-title":"Biomark Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.910100\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:21:15Z","timestamp":1655443275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.910100\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":91,"alternative-id":["10.3389\/fcvm.2022.910100"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.910100","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"article-number":"910100"}}